Inogen (NASDAQ:INGN) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a report released on Tuesday.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Stock Up 1.0 %

INGN stock opened at $10.05 on Tuesday. The company has a 50 day moving average of $9.82 and a two-hundred day moving average of $9.52. Inogen has a 12-month low of $4.93 and a 12-month high of $13.33. The company has a market cap of $239.39 million, a price-to-earnings ratio of -4.47 and a beta of 1.04.

Institutional Trading of Inogen

Several large investors have recently added to or reduced their stakes in INGN. Meeder Asset Management Inc. acquired a new stake in shares of Inogen in the 2nd quarter valued at $30,000. Quarry LP acquired a new stake in shares of Inogen in the third quarter worth about $59,000. CWM LLC boosted its stake in shares of Inogen by 2,185.9% during the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock worth $54,000 after acquiring an additional 6,339 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Inogen during the 1st quarter valued at about $81,000. Finally, Pitcairn Co. bought a new position in shares of Inogen in the 1st quarter valued at approximately $86,000. 89.94% of the stock is owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.